hemodiluted stent with metformin for prevention of intracoronary restenosis

摘要

HEMODILUTED STENT PATENT WITH METFORMINE MEDICINE FOR PREVENTION OF INTRACORONARY RESTENOSIS is a combination of hemodiluted stenting and insulin resistance modulator used against cardiovascular diseases that are the leading cause of death in the globalized world. There is a clear correlation between weight gain and overweight with risk of cardiovascular disease. Overweight predisposes to these diseases due to abnormalities in lipid metabolism, glucose and blood pressure. Insulin resistance / hyperinsulinemia appears to be a risk factor independent of other associated risk factors such as obesity, hyperlipidemia and hypertension in both men and women. Insulin and insulin-like growth factors stimulate smooth muscle cell activity and are involved in atherogenesis and even restenosis following coronary repair by angioplasty. Other effects of insulin are related to the mechanisms that contribute to the development of both hypertension, myocardial hypertrophy, cell proliferation, vascular hypertrophy, coagulation processes, dyslipidemia, contributing to intracoronary restenosis after endaprotesis implantation. HEMODILUTED STENT PATENT WITH METFORMIN MEDICINE FOR PREVENTION OF INTRACORONARY RESTENOSIS markedly decreases this deleterious vascular process, since the combination of endoprosthesis with local vascular flow improvement, and the resistance modulating functions of the hernodiluid drug, is the perfect combination for decreased cardiovascular events, myocardial infarction and death.